These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 9559490)

  • 1. Bolstering Sisyphus.
    Van Buskirk EM
    J Glaucoma; 1998 Apr; 7(2):73-4. PubMed ID: 9559490
    [No Abstract]   [Full Text] [Related]  

  • 2. Situation with glaucoma and the state of mind in the glaucoma community.
    Kotik J
    J Glaucoma; 1998 Dec; 7(6):446-7. PubMed ID: 9871870
    [No Abstract]   [Full Text] [Related]  

  • 3. Mean standard deviations for common glaucoma treatments.
    Stewart WC; Stewart JA; Nelson LA; Kruft B
    Acta Ophthalmol; 2009 Feb; 87(1):112-4. PubMed ID: 18494738
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of medications and surgery on intraocular pressure fluctuation.
    Sit AJ; Asrani S
    Surv Ophthalmol; 2008 Nov; 53 Suppl1():S45-55. PubMed ID: 19038624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of glaucoma treatment over a patient lifetime: a Markov model (letter).
    Kymes S
    J Glaucoma; 2006 Oct; 15(5):471-2; author reply 472-3. PubMed ID: 16988613
    [No Abstract]   [Full Text] [Related]  

  • 6. Progressive normal-tension Glaucoma.
    Girkin CA; Chauhan BC; Medeiros FA
    J Glaucoma; 2008; 17(7):591-3. PubMed ID: 18854739
    [No Abstract]   [Full Text] [Related]  

  • 7. The European Glaucoma Prevention Study and the Ocular Hypertension Treatment Study: why do two studies have different results?
    Parrish RK
    Curr Opin Ophthalmol; 2006 Apr; 17(2):138-41. PubMed ID: 16552248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness.
    Brown GC; Brown MM
    Ophthalmology; 2008 Aug; 115(8):1433; author reply 1433-4. PubMed ID: 18675701
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness.
    Tuulonen A; Azuara-Blanco A
    Ophthalmology; 2009 Jan; 116(1):166-7; author reply 167. PubMed ID: 19118707
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fogagnolo P
    Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure.
    Choplin N; Bernstein P; Batoosingh AL; Whitcup SM;
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S19-25. PubMed ID: 15016558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness.
    Lichter PR
    Ophthalmology; 2008 Oct; 115(10):1852-3; author reply 1853. PubMed ID: 18929170
    [No Abstract]   [Full Text] [Related]  

  • 13. Uniocular drug trials.
    Rotchford AP; King AJ
    Ophthalmology; 2004 Dec; 111(12):2315; author reply 2315-6. PubMed ID: 15582097
    [No Abstract]   [Full Text] [Related]  

  • 14. Ocular hypertension.
    Gopal KS
    Indian J Ophthalmol; 2004 Sep; 52(3):257-8; author reply 258-9. PubMed ID: 15510475
    [No Abstract]   [Full Text] [Related]  

  • 15. Intraocular pressure elevation within the first 24 hours after cataract surgery in patients with glaucoma or exfoliation syndrome.
    Levkovitch-Verbin H; Habot-Wilner Z; Burla N; Melamed S; Goldenfeld M; Bar-Sela SM; Sachs D
    Ophthalmology; 2008 Jan; 115(1):104-8. PubMed ID: 17561259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uniocular drug trial.
    Jones R; Triana MI; Zaslow K; Sponsel WE
    Ophthalmology; 2005 Jun; 112(6):1170; author reply 1170-1. PubMed ID: 15936449
    [No Abstract]   [Full Text] [Related]  

  • 17. [Steroid induced ocular hypertension and glaucoma].
    Călugăru D; Călugăru M
    Oftalmologia; 2009; 53(3):15-33. PubMed ID: 19899544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination.
    Konstas AG; Papapanos P; Tersis I; Houliara D; Stewart WC
    Ophthalmology; 2003 Jul; 110(7):1357-60. PubMed ID: 12867391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Invernizzi T; Bottoli A; Autelitano A
    Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [An observational, retrospective two-year cost study in primary open-angle glaucoma and ocular hypertension in newly diagnosed patients].
    Rouland JF; Peigne G; Sellem E; Renard JP; Williamson W; Filippi JM; Cohn H; Hamard P; Abellan P; Chagnon A; Malet F; Haye I
    J Fr Ophtalmol; 2001 Mar; 24(3):233-43. PubMed ID: 11285438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.